I N S T A N D e. V. Gesellschaft zur Förderung der Qualitätssicherung in medizinischen Laboratorien e. V. (vormals Hämometerprüfstelle)
|
|
- Albert Matthews
- 6 years ago
- Views:
Transcription
1 I N S T A N D e. V. Gesellschaft zur Förderung der Qualitätssicherung in medizinischen Laboratorien e. V. (vormals Hämometerprüfstelle) WHO Collaborating Centre for Quality Assurance and Standardization in Laboratory Medicine in cooperation with Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) Gesellschaft für Virologie (GfV) Deutsche Gesellschaft für Hygiene und Mikrobiologie (DGHM) INSTAND-Geschäftsstelle Ubierstr Düsseldorf Telefon: +49 (0) Fax: +49 (0) instand@instand-ev.de Internet: EQAS Adviser: Assistant EQAS Adviser: Prof. Dr. Heinz Zeichhardt Dr. Hans-Peter Grunert CharitéCentrum für diagnostische und präventive Labormedizin Institut für Biotechnologische Diagnostik in der GBD Institut für Virologie, Campus Benjamin Franklin Potsdamer Chaussee 80, Berlin Hindenburgdamm 27, Berlin Tel.: +49-(0) ; Fax: +49-(0) Tel.: +49-(0) /23; Fax: +49-(0) HPGrunert@gmx.de Heinz.Zeichhardt@charite.de August 2011 Final Report External Quality Assessment Scheme (EQAS) - June/July 2011 Virus Genome Detection - Human Papilloma Viruses (373) Differentiation of High Risk and Low Risk Types and Typing (PCR/NAT HPV) INSTAND-Target Value Laboratories: Uniklinik Köln, Institut für Virologie, Nationales Referenzzentrum für Papillom- und Polyomaviren: Prof. Dr. H. Pfister, Prof. Dr. U. Wieland, Dr. R. Kaiser Charité - Universitätsmedizin Berlin, Campus Mitte, Institut für Medizinische Virologie, Nationales Konsiliarlaboratorium für Hantaviren: Prof. Dr. D. H. Krüger, PD Dr. J. Hofmann Klinikum der Johann Wolfgang Goethe-Universität, Institut für Medizinische Virologie, Frankfurt/Main: Prof. Dr. H. W. Doerr, Prof. Dr. H. Rabenau, PD Dr. A. Berger, Dr. R. Allwinn Labor Enders, Institut für Virologie, Infektiologie und Epidemiologie, Stuttgart: Prof. Dr. Gisela Enders & Partner Universitätsklinikum des Saarlandes, Institut für Virologie, Homburg/Saar; Prof. Dr. S. Smola, Prof. Dr. N. Müller-Lantzsch 373 Human Papilloma Viruses Genome June July 2011 Letter a.doc 1
2 Dear colleagues, Attached please find the final report for the EQAS "PCR-/NAT-HPV". Your certificate of successful participation, statement of participation and statement of your individual (validity period: 12 months) were sent out independently. The following test categories are individually stated on the documents: 20. Differentiation between "High Risk"- and "Low Risk" HPV - Differenzierung von HPV in "High Risk"- und "Low Risk"-Typen 25. Typing of "High Risk" HPV and detection of "Low Risk" HPV (without typing) - Typisierung von "High Risk"-HPV und Nachweis von "Low Risk"-HPV (ohne Typisierung) 30. Typing of HPV - Typisierung von HPV 35. Typing of "High Risk" HPV (without determination of "Low Risk" HPV) - Typisierung von "High Risk"-HPV (ohne Bestimmung von "Low Risk"-HPV) 60. Determination of "High Risk" HPV (without determination of "Low Risk" HPV) - Bestimmung von "High Risk"-HPV (ohne Bestimmung von "Low Risk"-HPV) The report for this EQA scheme is also available as PDF file on the INSTAND-Homepage under EQAS / Reports / Year and Category (Virus genome detection) in English language ( ) and German language ( ). Sample properties and evaluation In this EQAS the test are requested as follows for: Differentiation: High Risk, Low Risk, " or "indeterminate ; Typing: HPV (e.g. HPV 6 = 6 = human papilloma virus 6 ) Sample properties were as follows: Sample : positive; lysate of HeLa cells, containing sequences of. Sample : HPV 16 low positive; lysate of SiHa cells, containing sequences of HPV 16. Please see comment to sample Sample : Biopsy material of a condyloma. The biopsy material is HPV 6 positive as analyzed by the INSTAND-Target Value Laboratories. Sample : positive; lysate of HeLa cells, containing sequences of. Sample : HPV ; lysate of MRC-5 cells (human lung fibroblasts), no HPV genome detectable. The positive samples and represented different dilution steps of a dilution series of a lysate of HeLa cells. Please see table 1 for details on sample properties, and success rates. A result was not considered for evaluation in case you had specified that this result should only be taken as additional information and ignored as valid result. For receiving a certificate of successful participation it is required that you analyzed all 5 samples of the sample set ly with the same method in the corresponding test categories (100 ). The evaluation criteria for the of EQA schemes in virology follow the new Guideline of the German Medical Association (Bundesärztekammer/ RiliBÄK = Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen). Please see section B2 of the RiliBÄK "qualitative determinations in laboratory medicine = Qualitative laboratoriumsmedizinische Untersuchungen" (effective since with a transition period of two years; Deutsches Ärzteblatt, Jg. 108, Heft 30, , Seite A ). Section B3 of the RiliBÄK "direct detection and characterization of infectious diseases pathogens = Direkter Nachweis und Charakterisierung von Infektionserregern" is in progress. Results The are summarized and differentiated for each sample according to test category 20, 25, 30, 35 and 60, respectively, in table 1. Detailed for the detection and differentiation between "High Risk" and "Low Risk" HPVs as well as for typing are shown in the following tables. Comment to sample : Sample is low positive for HPV 16 due to the adjusted concentration of SiHa cells, which contain sequences of HPV 16. The INSTAND-Target Value Laboratories pre-tested this sample. Laboratories which applied PCR test systems reported HPV positive for this sample whereas a laboratory which used a 373 Human Papilloma Viruses Genome June July 2011 Letter a.doc 2
3 hybridization test (e.g. HPV screening test principle Hybrid Capture 2 Technology/Qiagen) reported. It could already be shown in previous EQA schemes that screening by hybridization methods for the detection of "High Risk" HPV s revealed a lower analytical sensitivity in comparison to PCR detection methods. In this EQA scheme those for sample which were received by application of the HPV-screening test "Hybrid Capture 2 Technology/Qiagen" were not evaluated for test categories 20 and 60 (without disadvantage for the certificate). The manufacturer concerned has already been informed. In recent years samples containing "High Risk" or "Low Risk" HPV s in different concentrations have sporadically been included into the EQA schemes in order to get insight into the analytical sensitivities of the different applied test systems. Objective of the INSTAND EQA schemes is to assess the performance of screening methods in comparison to the more sensitive PCR test systems including consecutive typing. The question of different analytical sensitivities of diverse methods for the detection of HPV was already addressed by the Jointed Diagnostic Council of the Deutsche Vereinigung zur Bekämpfung von Viruskrankheiten (DVV) and the Gesellschaft für Virologie (GfV) in accordance with Prof. Dr. H. Pfister, Director of the Nationales Referenzzentrum für Papillom- und Polyomaviren, Uniklinik Köln, Institut für Virologie, in August Test systems which show differences in analytical sensitivity are desirable and should be applied depending on the clinical status of the patient. The lower sensitivity of hybrid capture tests can be adequate or even of advantage for screening of cervical carcinoma and early detection of cervical intraepithelial neoplasia (CIN) under the prerequisite that these tests are able to detect not only HPV 16 and but also relevant "High Risk" HPV s. Enhanced sensitivity of PCR/NAT for the detection of HPV genome is desirable for: the detection of adenocarcinoma and for the early detection of adenocarcinoma in situ, the triage of women with cytologic diagnosis ASCUS (atypical squamous cells of undetermined significance), the control of women after therapy. Typing of HPV by PCR/NAT is reasonable for: the differentiation between reactivation of persisting HPV infection and primary infection/reinfection with a new HPV, the detection of multiple HPV s in immunocompromised patients. Comments to test categories Test category 35: Typing of "High Risk" HPV (without determination of "Low Risk" HPV) These tests exclusively detect and "High Risk" HPV and cannot detect "Low Risk" HPV. This means that a test result obtained by these tests can only be interpreted as " for High Risk" HPV. Results representing " for High Risk HPV" will be stated as "" in your statement of individual. Test category 60: Determination of "High Risk" HPV (without determination of "Low Risk" HPV) These tests exclusively detect "High Risk" HPV (without specification of the HPV ) and cannot detect "Low Risk" HPV. This means that a test result obtained by these tests can only be interpreted as " for High Risk HPV". Results representing " for High Risk HPV" will be stated as "" in your statement of individual. Determination of "High Risk HPV E6/E7 mrna One laboratory applied a TMA test for the detection of "High Risk HPV E6/E7 mrna. This test was assigned to test category 60 because this test system only detects E6/E7 mrna of a distinct number of "High Risk" HPV s. We gratefully acknowledge the good cooperation with Prof. Dr. H. Pfister, Prof. Dr. U. Wieland and Dr. R. Kaiser (Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Universität Köln) as well as Prof. Dr. H.-P. Berlien and Dr. U. Müller (Evangelische Elisabeth Klinik, Berlin). We additionally thank Dr. M. Enders and Dr. G. Schalasta (Labor Prof. Gisela Enders und Partner, Stuttgart) for the studies on suitability of the EQA samples for the detection of "High Risk" HPV E6/E7 mrna by a TMA test system. Thank you very much for your kind cooperation. Prof. Dr. H. Zeichhardt 373 Human Papilloma Viruses Genome June July 2011 Letter a.doc 3
4 Properties High Risk or Low Risk Table 1: Summary of sample properties, and success rates Sample * Sample # Sample Sample * Sample HPV positive HPV positive # HPV positive HPV positive HPV High Risk High Risk # Low Risk High Risk Type # 6 18 Material lysate of HeLa cells lysate of SiHa cells # biopsy material lysate of HeLa cells lysate of MRC-5 cells Dilution 1 : 50* 1 : : 25 1 : 100* --- Success rates for all 5 samples of the sample set & considered as for test category 20: differentiation between "High Risk" and "Low Risk" HPV (human papilloma viruses) High Risk High Risk # Low Risk High Risk # (91/92) (57/62) # (90/92) (87/92) (91/92) considered as for test category 25: typing of "High Risk" HPV and detection of "Low Risk" HPV (without typing) HPV 16 Low Risk / not done 100 (7/7) 100 (7/7) 100 (7/7) 100 (7/7) considered as for test category 30: typing of HPV HPV 16 HPV 6 / not done 98.7 (76/77) 92.2 (71/77) 100 (78/78) 97.4 (75/77) 100 (7/7) 98.7 (76/77) considered as for test category 35: typing of "High Risk" HPV (without determination of "Low Risk" HPV) HPV 16 for High Risk-HPV for High Risk-HPV 100 (8/8) 100 (8/8) 100 (7/7) considered as for test category 60: determination of "High Risk" HPV (without determination of "Low Risk" HPV) High Risk High Risk # for High Risk-HPV High Risk for High Risk-HPV # (17/18) (11/11) # (17/18) (18/18) (17/18) * Samples represent different dilution steps of the same dilution series of a lysate of HeLa cells. # Sample is low positive for HPV 16 due to the adjusted concentration of SiHa cells, which contain sequences of HPV 16. The for the HPV screening test principle "Hybrid Capture 2 Technology/Qiagen" reported for test categories 20 and 60, respectively, were not evaluated (without disadvantage for the certificate). For details see comment to sample & The success rates for all 5 samples of the corresponding sample set of test categories 20, 25, 30, 35 and 60, respectively, refer to the number of participating laboratories. Laboratories having reported obtained by several methods are recorded only once in the corresponding test category. 100 (8/8) 100 (8/8) 91.1 &# (82/90) 100 & (7/7) 88.2 & (67/76) 100 & (7/8) 88.9 &# (16/18) 373 Human Papilloma Viruses Genome June July 2011 Letter a.doc 4
5 INSTAND e. V., Gesellschaft zur Förderung der Qualitätssicherung in medizinischen Laboratorien e. V. (vormals Hämometerprüfstelle) - in cooperation with Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten e. V. (DVV) Gesellschaft für Virologie e. V. (GfV) Deutsche Gesellschaft für Hygiene und Mikrobiologie e. V. (DGHM) EQAS Virology June/July 2011 Virus genome detection PCR- / NAT-HPV (Human Papilloma Viruses) (373) Results for sample Differentiation between "High Risk" and "Low Risk" HPV Correct result: High Risk test in High Risk Low Risk indeterminate High Risk Low Risk indeterminate hybridization (70) Chipron / Chipron Gen ID (AID) / Gen ID (AID) Genomica / Genomica Greiner / Greiner Innogenetics / Innogenetics Roche / Roche in house / Qiagen in house / Roche in house / manuf manuf. / manuf nested PCR / hybridization (1270) in house / in house Abbott / Abbott hybridization / hybridization (3070) Qiagen / Qiagen PCR / hybridization (9870) astra Diag. / astra Diag sequencing (72) PCR / sequencing (1172) in house / in house nested PCR / sequencing (1272) in house / in house TaqMan / sequencing (1372) manuf. / manuf test (99) PCR / test (1199) in house / in house nested PCR / test (1299) in house / in house Human Papilloma Viruses Genome June July 2011 Table a.doc 1
6 Results for sample Typing of "High Risk" HPV and detection of "Low Risk" HPV (without typing) Correct result: test in hybridization (70) Gen ID (AID) / Gen ID (AID) test (99) PCR / test (1199) in house / in house LightCycler / test (4099) in house / in house Typing of HPV Correct result: test in Results for sample hybridization (70) Chipron / Chipron Gen ID (AID) / Gen ID (AID) Genomica / Genomica 1 1 a Greiner / Greiner Innogenetics / Innogenetics b, c Roche / Roche in house / Roche in house / in house in house / manufacturer manufacturer / manufact nested PCR / hybridization (1270) in house / in house andere PCR / hybridization (9870) astra Diag. / astra Diag. 1 1 d 0.0 a One participant detected additionally HPV 45. b One participant detected additionally HPV 39, HPV 68 and HPV 73. c One participant detected additionally HPV 39. d The sample comprises exclusively "High Risk" HPV 18. Therefore the reporting of "Low Risk" HPV 42, HPV 43 and HPV 44 was assessed as "in" result. 373 Human Papilloma Viruses Genome June July 2011 Table a.doc 2
7 30. Typing of HPV (continued) Results for sample sequencing (72) PCR / sequencing (1172) in house / in house nested PCR / sequencing (1272) in house / in house TaqMan / sequencing (1372) manufacturer / manufact test (99) PCR / test (1199) AmpliSens / AmpliSens in house / in house TaqMan / test (1399) Roche / Roche Results for sample Typing of "High Risk" HPV (without determination of "Low Risk" HPV) (Tests for exclusive detection and typing of "High Risk"-HPV )* Correct result: test in * * hybridization (70) Abbott / Abbott test (99) TaqMan / test (1399) Roche / Roche * These tests exclusively detect and "High Risk"-HPV and cannot detect "Low Risk"-HPV. This means that a test result obtained by these tests can only be interpreted as " for High Risk-HPV". Results representing " for High Risk-HPV" will be stated as "" in your statement of individual. 373 Human Papilloma Viruses Genome June July 2011 Table a.doc 3
8 Results for sample Determination of "High Risk" HPV (without determination of "Low Risk" HPV) (Tests which exclusively detect "High Risk"-HPV)* Correct result: High Risk test in High Risk Low Risk indeterminate below level of * High Risk Low Risk indeterminate below level of * hybridization (70) Roche / Roche Abbott / Abbott hybridization / hybridization (3070) Qiagen / Qiagen test (99) PCR / test (1199) manuf. / manuf TMA / test (6099) Gen-Probe / Gen-Probe * These tests exclusively detect "High Risk"-HPV (without specification of the HPV ) and cannot detect "Low Risk"-HPV. This means that a test result obtained by these tests can only be interpreted as " for High Risk-HPV". Results representing " for High Risk-HPV" will be stated as "" in your statement of individual. 373 Human Papilloma Viruses Genome June July 2011 Table a.doc 4
9 Results for sample Differentiation between "High Risk" and "Low Risk" HPV Correct result: High Risk test in High Risk Low Risk indeterminate evaluated without evaluation # hybridization (70) # hybridization / hybridization (3070) # Qiagen / Qiagen # # 30 # High Risk Low Risk indeterminate 57 2 # 2 # 0 0 # 1 2 # 2 # 4 26 # 26 # 91.9 hybridization (70) Chipron / Chipron Gen ID (AID) / Gen ID (AID) Genomica / Genomica Greiner / Greiner Innogenetics / Innogenetics Roche / Roche in house / Qiagen in house / Roche in house / manuf manuf. / manuf nested PCR / hybridization (1270) in house / in house Abbott / Abbott PCR / hybridization (9870) astra Diag. / astra Diag sequencing (72) PCR / sequencing (1172) in house / in house nested PCR / sequencing (1272) in house / in house TaqMan / sequencing (1372) manuf. / manuf test (99) PCR / test (1199) in house / in house nested PCR / test (1299) in house / in house # Results without evaluation: please see comment to sample Human Papilloma Viruses Genome June July 2011 Table a.doc 5
10 Results for sample Typing of "High Risk" HPV and detection of "Low Risk" HPV (without typing) Correct result: HPV 16 test in HPV HPV 16 hybridization (70) Gen ID (AID) / Gen ID (AID) test (99) PCR / test (1199) in house / in house LightCycler / test (4099) in house / in house Typing of HPV Correct result: HPV 16 test in Results for sample HPV HPV 16 hybridization (70) Chipron / Chipron Gen ID (AID) / Gen ID (AID) Genomica / Genomica Greiner / Greiner Innogenetics / Innogenetics Roche / Roche in house / Roche in house / in house in house / manufacturer manufacturer / manufact nested PCR / hybridization (1270) in house / in house andere PCR / hybridization (9870) astra Diag. / astra Diag Human Papilloma Viruses Genome June July 2011 Table a.doc 6
11 30. Typing of HPV (continued) Results for sample sequencing (72) PCR / sequencing (1172) in house / in house nested PCR / sequencing (1272) in house / in house TaqMan / sequencing (1372) manufacturer / manufact test (99) PCR / test (1199) AmpliSens / AmpliSens in house / in house TaqMan / test (1399) Roche / Roche Results for sample Typing of "High Risk" HPV (without determination of "Low Risk" HPV) (Tests for exclusive detection and typing of "High Risk"-HPV )* Correct result: HPV 16 test in HPV 16 * HPV 16 * hybridization (70) Abbott / Abbott test (99) TaqMan / test (1399) Roche / Roche * These tests exclusively detect and "High Risk"-HPV and cannot detect "Low Risk"-HPV. This means that a test result obtained by these tests can only be interpreted as " for High Risk-HPV". Results representing " for High Risk-HPV" will be stated as "" in your statement of individual. 373 Human Papilloma Viruses Genome June July 2011 Table a.doc 7
12 Results for sample Determination of "High Risk" HPV (without determination of "Low Risk" HPV) (Tests which exclusively detect "High Risk"-HPV)* Correct result: High Risk test in High Risk Low Risk indeterminate evaluated without evaluation # hybridization (70) # hybridization / hybridization (3070) # Qiagen / Qiagen # 11 High Risk Low Risk indeterminate 7 # 7 # 11 3 # 3 # 0 0 # 0 0 # below level of * 0 4 # 4 # below level of * hybridization (70) Roche / Roche Abbott / Abbott test (99) PCR / test (1199) manuf. / manuf TMA / test (6099) Gen-Probe / Gen-Probe * These tests exclusively detect "High Risk"-HPV (without specification of the HPV ) and cannot detect "Low Risk"-HPV. This means that a test result obtained by these tests can only be interpreted as " for High Risk-HPV". Results representing " for High Risk-HPV" will be stated as "" in your statement of individual. # Results without evaluation: please see comment to sample Human Papilloma Viruses Genome June July 2011 Table a.doc 8
13 Results for sample Differentiation between "High Risk" and "Low Risk" HPV Correct result: Low Risk test in High Risk Low Risk indeterminate High Risk Low Risk indeterminate hybridization (70) Chipron / Chipron Gen ID (AID) / Gen ID (AID) Genomica / Genomica Greiner / Greiner Innogenetics / Innogenetics Roche / Roche in house / Qiagen in house / Roche in house / manuf manuf. / manuf nested PCR / hybridization (1270) in house / in house astra Diag. / astra Diag hybridization / hybridization (3070) Qiagen / Qiagen PCR / hybridization (9870) astra Diag. / astra Diag sequencing (72) PCR / sequencing (1172) in house / in house nested PCR / sequencing (1272) in house / in house TaqMan / sequencing (1372) manuf. / manuf test (99) PCR / test (1199) in house / in house nested PCR / test (1299) in house / in house Human Papilloma Viruses Genome June July 2011 Table a.doc 9
14 Results for sample Typing of "High Risk" HPV and detection of "Low Risk" HPV (without typing) Correct result: Low Risk test in hybridization (70) Gen ID (AID) / Gen ID (AID) test (99) PCR / test (1199) in house / in house LightCycler / test (4099) in house / in house Typing of HPV Correct result: HPV 6 test in Results for sample HPV HPV 6 hybridization (70) Chipron / Chipron 7 7 a Gen ID (AID) / Gen ID (AID) Genomica / Genomica Greiner / Greiner 9 9 a Innogenetics / Innogenetics a Roche / Roche in house / Roche in house / in house in house / manufacturer manufacturer / manufact nested PCR / hybridization (1270) in house / in house andere PCR / hybridization (9870) astra Diag. / astra Diag. 2 2 a a In 11 participants detected additionally HPV Human Papilloma Viruses Genome June July 2011 Table a.doc 10
15 30. Typing of HPV (continued) Results for sample HPV 6 sequencing (72) PCR / sequencing (1172) in house / in house nested PCR / sequencing (1272) in house / in house TaqMan / sequencing (1372) manufacturer / manufact test (99) PCR / test (1199) AmpliSens / AmpliSens in house / in house Results for sample Typing of "High Risk" HPV (without determination of "Low Risk" HPV) (Tests for exclusive detection and typing of "High Risk"-HPV )* Correct result: for "High Risk" HPV test in HPV 6 * HPV 6 * hybridization (70) Abbott / Abbott test (99) TaqMan / test (1399) Roche / Roche * These tests exclusively detect and "High Risk"-HPV and cannot detect "Low Risk"-HPV. This means that a test result obtained by these tests can only be interpreted as " for High Risk-HPV". Results representing " for High Risk-HPV" will be stated as "" in your statement of individual. 373 Human Papilloma Viruses Genome June July 2011 Table a.doc 11
16 Results for sample Determination of "High Risk" HPV (without determination of "Low Risk" HPV) (Tests which exclusively detect "High Risk"-HPV)* Correct result: for "High Risk" HPV test in High Risk Low Risk indeterminate below level of * High Risk Low Risk indeterminate below level of * hybridization (70) Roche / Roche Abbott / Abbott hybridization / hybridization (3070) Qiagen / Qiagen test (99) PCR / test (1199) manuf. / manuf TMA / test (6099) Gen-Probe / Gen-Probe * These tests exclusively detect "High Risk"-HPV (without specification of the HPV ) and cannot detect "Low Risk"-HPV. This means that a test result obtained by these tests can only be interpreted as " for High Risk-HPV". Results representing " for High Risk-HPV" will be stated as "" in your statement of individual. 373 Human Papilloma Viruses Genome June July 2011 Table a.doc 12
17 Results for sample Differentiation between "High Risk" and "Low Risk" HPV Correct result: High Risk test in High Risk Low Risk indeterminate High Risk Low Risk indeterminate hybridization (70) Chipron / Chipron Gen ID (AID) / Gen ID (AID) Genomica / Genomica Greiner / Greiner Innogenetics / Innogenetics Roche / Roche in house / Qiagen in house / Roche in house / manuf manuf. / manuf nested PCR / hybridization (1270) in house / in house Abbott / Abbott hybridization / hybridization (3070) Qiagen / Qiagen PCR / hybridization (9870) astra Diag. / astra Diag sequencing (72) PCR / sequencing (1172) in house / in house nested PCR / sequencing (1272) in house / in house TaqMan / sequencing (1372) manuf. / manuf test (99) PCR / test (1199) in house / in house nested PCR / test (1299) in house / in house Human Papilloma Viruses Genome June July 2011 Table a.doc 13
18 Results for sample Typing of "High Risk" HPV and detection of "Low Risk" HPV (without typing) Correct result: test in hybridization (70) Gen ID (AID) / Gen ID (AID) test (99) PCR / test (1199) in house / in house LightCycler / test (4099) in house / in house Typing of HPV Correct result: Results for sample test in hybridization (70) Chipron / Chipron Gen ID (AID) / Gen ID (AID) Genomica / Genomica Greiner / Greiner Innogenetics / Innogenetics a, b Roche / Roche in house / Roche in house / in house in house / manufacturer manufacturer / manufact nested PCR / hybridization (1270) in house / in house andere PCR / hybridization (9870) astra Diag. / astra Diag. 1 1 c 0.0 a One participant detected additionally HPV 39, HPV 68 and HPV 73. b One participant detected additionally HPV 39. c Sample comprises exclusively "High Risk" HPV 18. Therefore the reporting of "Low Risk" HPV 42, HPV 43 and HPV 44 was assessed as "in" result. 373 Human Papilloma Viruses Genome June July 2011 Table a.doc 14
19 30. Typing of HPV (continued) Results for sample sequencing (72) PCR / sequencing (1172) in house / in house nested PCR / sequencing (1272) in house / in house TaqMan / sequencing (1372) manufacturer / manufact test (99) PCR / test (1199) AmpliSens / AmpliSens in house / in house TaqMan / test (1399) Roche / Roche Results for sample Typing of "High Risk" HPV (without determination of "Low Risk" HPV) (Tests for exclusive detection and typing of "High Risk"-HPV )* Correct result: test in * * hybridization (70) Abbott / Abbott test (99) TaqMan / test (1399) Roche / Roche * These tests exclusively detect and "High Risk"-HPV and cannot detect "Low Risk"-HPV. This means that a test result obtained by these tests can only be interpreted as " for High Risk-HPV". Results representing " for High Risk-HPV" will be stated as "" in your statement of individual. 373 Human Papilloma Viruses Genome June July 2011 Table a.doc 15
20 Results for sample Determination of "High Risk" HPV (without determination of "Low Risk" HPV) (Tests which exclusively detect "High Risk"-HPV)* Correct result: High Risk test in High Risk Low Risk indeterminate below level of * High Risk Low Risk indeterminate below level of * hybridization (70) Roche / Roche Abbott / Abbott hybridization / hybridization (3070) Qiagen / Qiagen test (99) PCR / test (1199) manuf. / manuf TMA / test (6099) Gen-Probe / Gen-Probe * These tests exclusively detect "High Risk"-HPV (without specification of the HPV ) and cannot detect "Low Risk"-HPV. This means that a test result obtained by these tests can only be interpreted as " for High Risk-HPV". Results representing " for High Risk-HPV" will be stated as "" in your statement of individual. 373 Human Papilloma Viruses Genome June July 2011 Table a.doc 16
21 Results for sample Differentiation between "High Risk" and "Low Risk" HPV Correct result: test in High Risk Low Risk indeterminate High Risk Low Risk indeterminate hybridization (70) Chipron / Chipron Gen ID (AID) / Gen ID (AID) Genomica / Genomica Greiner / Greiner Innogenetics / Innogenetics Roche / Roche in house / Qiagen in house / Roche in house / manuf manuf. / manuf nested PCR / hybridization (1270) in house / in house Abbott / Abbott hybridization / hybridization (3070) Qiagen / Qiagen PCR / hybridization (9870) astra Diag. / astra Diag sequencing (72) PCR / sequencing (1172) in house / in house nested PCR / sequencing (1272) in house / in house TaqMan / sequencing (1372) manuf. / manuf test (99) PCR / test (1199) in house / in house nested PCR / test (1299) in house / in house Human Papilloma Viruses Genome June July 2011 Table a.doc 17
22 Results for sample Typing of "High Risk" HPV and detection of "Low Risk" HPV (without typing) Correct result:, not done test in / not done not done hybridization (70) Gen ID (AID) / Gen ID (AID) test (99) PCR / test (1199) in house / in house LightCycler / test (4099) in house / in house Typing of HPV Correct result:, not done Results for sample test in not done not done hybridization (70) Chipron / Chipron Gen ID (AID) / Gen ID (AID) 8 7 a 87.5 Genomica / Genomica Greiner / Greiner Innogenetics / Innogenetics Roche / Roche in house / Roche in house / in house in house / manufacturer manufacturer / manufact nested PCR / hybridization (1270) in house / in house andere PCR / hybridization (9870) astra Diag. / astra Diag a One participant did not report any result for sample Human Papilloma Viruses Genome June July 2011 Table a.doc 18
23 30. Typing of HPV (continued) Results for sample sequencing (72) PCR / sequencing (1172) in house / in house nested PCR / sequencing (1272) in house / in house TaqMan / sequencing (1372) manufacturer / manufact test (99) PCR / test (1199) AmpliSens / AmpliSens in house / in house TaqMan / test (1399) Roche / Roche Results for sample Typing of "High Risk" HPV (without determination of "Low Risk" HPV) (Tests for exclusive detection and typing of "High Risk"-HPV )* Correct result: for "High Risk" HPV test in * * hybridization (70) Abbott / Abbott test (99) TaqMan / test (1399) Roche / Roche * These tests exclusively detect and "High Risk"-HPV and cannot detect "Low Risk"-HPV. This means that a test result obtained by these tests can only be interpreted as " for High Risk-HPV". Results representing " for High Risk-HPV" will be stated as "" in your statement of individual. 373 Human Papilloma Viruses Genome June July 2011 Table a.doc 19
24 Results for sample Determination of "High Risk" HPV (without determination of "Low Risk" HPV) (Tests which exclusively detect "High Risk"-HPV)* Correct result: for "High Risk" HPV test in High Risk Low Risk indeterminate below level of * High Risk Low Risk indeterminate below level of * hybridization (70) Roche / Roche Abbott / Abbott hybridization / hybridization (3070) Qiagen / Qiagen test (99) PCR / test (1199) manuf. / manuf TMA / test (6099) Gen-Probe / Gen-Probe * These tests exclusively detect "High Risk"-HPV (without specification of the HPV ) and cannot detect "Low Risk"-HPV. This means that a test result obtained by these tests can only be interpreted as " for High Risk-HPV". Results representing " for High Risk-HPV" will be stated as "" in your statement of individual. 373 Human Papilloma Viruses Genome June July 2011 Table a.doc 20
I N S T A N D e. V. Gesellschaft zur Förderung der Qualitätssicherung in medizinischen Laboratorien e. V. (vormals Hämometerprüfstelle)
I N S T A N D e. V. Gesellschaft zur Förderung der Qualitätssicherung in medizinischen Laboratorien e. V. (vormals Hämometerprüfstelle) WHO Collaborating Centre for Quality Assurance and Standardization
More informationHindenburgdamm 27, Berlin Tel.: +49-(0) ; Fax: +49-(0)
I S T A D e. V. Gesellschaft zur Förderung der Qualitätssicherung in medizinischen Laboratorien e. V. (vormals Hämometerprüfstelle) Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) Gesellschaft
More informationReport External Quality Assessment Scheme Group 346 Virus Immunology - Hepatitis C Virus November/December INSTAND e.v. in cooperation with:
Report External Quality Assessment Scheme Group 346 Virus Immunology - Hepatitis C Virus November/December 2014 INSTAND e.v. in cooperation with: Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten
More informationINSTAND e.v. in cooperation with:
Pre-evaluation of the EQA Schemes in Virus Diagnostics June 2015 Corrected version: 10 August 2015 (See Table 3; program 346) INSTAND e.v. in cooperation with: Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten
More informationReport External Quality Assessment Scheme Group 346 Virus Immunology - Hepatitis C Virus September INSTAND e.v. in cooperation with:
Report External Quality Assessment Scheme Group 346 Virus Immunology - Hepatitis C Virus September 2014 INSTAND e.v. in cooperation with: Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV)
More informationJune Pre-evaluation of the External Quality Assessment Schemes in Virus Diagnostics. Prof. Dr. Heinz Zeichhardt. Dr.
June 2018 Pre-evaluation of the External Quality Assessment Schemes in Virus Diagnostics Prof. Dr. Heinz Zeichhardt Dr. Martin Kammel Issued by: INSTAND Gesellschaft zur Förderung der Qualitätssicherung
More informationJune EQA schemes closed. Information on sample properties. Prof. Dr. Heinz Zeichhardt. Dr. Martin Kammel
June 2018 EQA schemes closed Information on sample properties Prof. Dr. Heinz Zeichhardt Dr. Martin Kammel Issued by: INSTAND Gesellschaft zur Förderung der Qualitätssicherung in medizinischen Laborarien
More informationINSTAND e.v. in cooperation with:
Pre-evaluation of the EQA Schemes in Virus Diagnostics November/December 2014 INSTAND e.v. in cooperation with: Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) Gesellschaft für Virologie
More informationINSTAND e.v. in cooperation with:
Pre-evaluation of the EQA Schemes in Virus Diagnostics November/December 2015 INSTAND e.v. in cooperation with: Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) Gesellschaft für Virologie
More informationSeptember Pre-evaluation of the External Quality Assessment Schemes in Virus Diagnostics
September 2016 of the External Quality Assessment Schemes in Virus Diagnostics Prof. Dr. Heinz Zeichhardt Priv.-Doz. Dr. Oliver Donoso Mantke Issued by: INSTAND Gesellschaft zur Förderung der Qualitätssicherung
More informationSeptember Pre-evaluation of the External Quality Assessment Schemes in Virus Diagnostics
September 2018 Corrected version: 20 November 2018 (See Table 3; page 9, program 344) of the External Quality Assessment Schemes in Virus Diagnostics Prof. Dr. Heinz Zeichhardt Dr. Martin Kammel Issued
More informationReport on External Quality Assessment Scheme Survey no. 253 Autoimmun Diseases 02 March 2015
Report on External Quality Assessment Scheme Survey no. 253 Autoimmun Diseases 2 March 15 INSTAND e.v. Dr. M. Blüthner Prof. Dr. Hans-Peter Seelig issued by: Instand e.v. Gesellschaft zur Förderung der
More informationNovember/ December 2016
November/ December 2016 Pre-evaluation of the External Quality Assessment Schemes in Virus Diagnostics Prof. Dr. Heinz Zeichhardt Dr. Martin Kammel Issued by: INSTAND Gesellschaft zur Förderung der Qualitätssicherung
More informationMarch Pre-evaluation of the External Quality Assessment Schemes in Virus Diagnostics
March 2018 Pre-evaluation of the External Quality Assessment Schemes in Virus Diagnostics deadline postponed : 23 March 2018 only for program 374: 06 April 2018 Prof. Dr. Heinz Zeichhardt Dr. Martin Kammel
More informationNovember/ December 2016
November/ December 2016 Corrected version: 02 February 2017 (See Table 3; page 11; program 401) EQA schemes closed Information on sample properties Prof. Dr. Heinz Zeichhardt Dr. Martin Kammel Issued by:
More informationINSTAND-Proficiency-Testing Program ACCOMPANYING BOOKLET
INSTAND-Proficiency-Testing Program ACCOMPANYING BOOKLET Testing Information Bacteriologic Infection Serology May 2014 I N S T A N D e. V. Gesellschaft zur Förderung der Qualitätssicherung in medizinischen
More informationFocus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection
HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).
More informationon the road to harmonisation?
on the road to harmonisation? Prof. Dr.med.Michael Spannagl Munich- Heart of? 1 O zapft is - Oktoberfest 1 Key facts Date: September - October (1 days) Location: Munich - Theresenwiese 6,3 Mio. Visitors
More informationfor Microbiology Novos programas de Controlo de Qualidade Externo: desenvolvimento e perspectivas 15 and 16 October 2008 Biognóstica - Portugal
for Microbiology Novos programas de Controlo de Qualidade Externo: desenvolvimento e perspectivas Overview Development of new schemes Molecular detection of mycobacteria Introduced as a new scheme in 2007
More informationHuman Papillomaviruses: Biology and Laboratory Testing
For our patients and our population Human Papillomaviruses: Biology and Laboratory Testing Geoffrey Higgins Microbiology and Infectious Diseases For our patients and our population HPV Associated Cancers
More informationVerification and validation of diagnostic laboratory tests in clinical virology
Journal of Clinical Virology 40 (2007) 93 98 Review Verification and validation of diagnostic laboratory tests in clinical virology Holger F. Rabenau a,, Harald H. Kessler b, Marhild Kortenbusch a, Andreas
More informationSTOCS-H Scottish TOC Study HPV test comparison
STOCS-H Scottish TOC Study HPV test comparison What is entailed? Trial of new HPV tests on residual sample after HC2 result obtained, reported and acted on Complements English Sentinel Sites HPV Multi-test
More informationfor Microbiology Quality Assessment Programmes for HPV and MRSA Effect of change to assessment categories for HBV DNA Dr Vivienne James SoGAT 2009
for Microbiology Quality Assessment Programmes for HPV and MRSA Effect of change to assessment categories for HBV DNA Dr Vivienne James Overview Update on the HPV scheme introduced in 2009 MRSA screening
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationClinical Practice Guidelines June 2013
Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early
More informationModelling Covariate Information in Multicenter Studies with Binary Outcome using Profile Likelihood
Medizinische Fakultät der Charité Universitätsmedizin Berlin Campus Benjamin Franklin aus dem Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie Direktor: Prof. Dr. Stefan N. Willich Modelling
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationB19 Virus EQA Programme Final Report QAV (B19DNA14)
B19 Virus 2014 EQA Programme Final Report QAV034116 (B19DNA14) Prof. Hubert GM Niesters Scientific Expert on behalf of QCMD Report authorised by the QCMD Executive in July 2014 A UKAS accredited proficiency
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationTechnical Report on the HPV LabNet 2011 HPV DNA Genotyping Proficiency Panel
Global Improvement in HPV genotyping services Technical Report on the HPV LabNet 2011 HPV DNA Genotyping Proficiency Panel Prepared by Carina Eklund 1, 2, Keng-Ling Wallin 3, Ola Forslund 1 & Joakim Dillner
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More information6th Interventional Workshop on Endovascular Stroke Therapy
Klinik für Diagnostische und Interventionelle Neuroradiologie Workshop for Physicians Fortbildung and MTRAs 6th Interventional Workshop on Endovascular Stroke Therapy For beginners and advanced learners
More informationPushing the Boundaries of the Lab Diagnosis in Asia
Pushing the Boundaries of the Lab Diagnosis in Asia Diana Lim MBBS, FRCPA, FRCPath (UK) Senior Consultant National University Health System and National University of Singapore Department of Pathology
More informationSafe, Confident, QIAsure
Safe, Confident, QIAsure A new cervical cancer screening test Sample to Insight QIAsure: A breakthrough solution in Women s Health We are at a turning point in the battle against cervical cancer. The global
More informationThe Predictors Studies (1, 2 & 3) A comparison of tests for high grade CIN in women with abnormal smears and in a screening population
The Predictors Studies (1, 2 & 3) A comparison of tests for high grade CIN in women with abnormal smears and in a screening population Jack Cuzick L Cadman, J Austin, D Mesher, A Ahmad, L Ambroisine, L
More informationEVIDENCE REPORT. Ass.-Prof. Dr. Gaby Sroczynski, M.P.H., Univ.-Prof. Dr. Uwe Siebert, M.P.H., M.Sc.
EVIDENCE REPORT Decision Analysis for the Evaluation of Benefits, Harms and Cost-effectiveness of Different Cervical Cancer Screening Strategies to Inform the S3 Clinical Guideline Prevention of Cervical
More informationHuman papillomavirus E6/E7 mrna testing has higher specificity than
1 Human papillomavirus E6/E7 mrna testing has higher specificity than DNA methods in the evaluation of cervical intraepithelial neoplasia Jochen Möckel 1, Jens Quaas 2, Helga Meisel 3, Anne-Sophie Endres
More informationCAMPUS INNENSTADT. 5. Münchener Kraepelin-Symposium and Symposium of the Clinical Research Group 241
KLINIKUM DER UNIVERSITÄT MÜNCHEN CAMPUS INNENSTADT KLINIK FÜR PSYCHIATRIE UND PSYCHOTHERAPIE INSTITUT FÜR PSYCHIATRISCHE PHÄNOMIK UND GENOMIK and Symposium of the Clinical Research Group 241 Recovery in
More information14. Cancer of the Cervix Uteri
KEY FACTS 14. Cancer of the Cervix Uteri ICD-9 180 On average 78 cases of invasive cervical cancer were registered per year. Half of cases occurred under 49 years of age. 2% of female cancers. Higher than
More informationEU guidelines for reporting gynaecological cytology
EU guidelines for reporting gynaecological cytology Amanda Herbert Guy s & St Thomas Foundation NHS Trust 5th EFCS Annual Tutorial, Trondheim, Norway 28 th May 1 st June 2012 EU guidelines aim to harmonize
More informationType-Specific Human Papillomavirus E6/E7 mrna Detection by Real-Time PCR Improves Identification of Cervical Neoplasia
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2011, p. 3794 3799 Vol. 49, No. 11 0095-1137/11/$12.00 doi:10.1128/jcm.00549-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Type-Specific
More informationThe Biology of HPV Infection and Cervical Cancer
The Biology of HPV Infection and Cervical Cancer Kaitlin Sundling, M.D., Ph.D. Clinical Instructor Faculty Director, Cytotechnology Program Wisconsin State Laboratory of Hygiene and University of Wisconsin
More informationWhy HPV Screening Which Problems What Methods
Lead Group Log HPV Testing & Screening Current Status & Future Screening HPV Andreas M. Kaufmann Why HPV Screening Which Problems What Methods Andreas M. Kaufmann Gynecologic Tumor Immunology Charité Campus
More informationHPV AND CERVICAL CANCER
HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND
More informationThe Value of the Residual "HPV Load" after Surgical Treatment of Cervical Intraepithelial Neoplasia
ISSN: 2578-4838 The Value of the Residual "HPV Load" after Surgical Treatment of Cervical Intraepithelial Neoplasia Cherenkov VG*, Alexandrov AS and Sycheva DN Novgorod State University, Yaroslav the Wise,
More informationPAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals
PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals Historical Named after George Papanicolaou, a Greek American Studied cervical epithelium in menstrual cycle of guinea
More informationRelationship between human papillomavirus infection and cervical cancer progression
21 Review Relationship between human papillomavirus and cervical cancer progression Meichang Ai Infection Management Section, The People's Hospital of Lincang, Lincang, China Keywords Human papillomavirus;
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationHepatitis C Virus (RNA)A
Hepatitis C Virus (RNA)A 2012 EQA Programme Final Report QAV994112 (HCVRNA12A) Professor Jacques Izopet Scientific Expert on behalf of QCMD Report authorised by the QCMD Executive in July 2012 A UKAS accredited
More informationFEDERAL PUBLIC SERVICE, HEALTH, FOOD CHAIN SECURITY AND ENVIRONMENT CLINICAL BIOLOGY COMMISSION CLINICAL BIOLOGY SECTION
IPH J. Wytsmanstreet 14 B-1050 Brussels FEDERAL PUBLIC SERVICE, HEALTH, FOOD CHAIN SECURITY AND ENVIRONMENT CLINICAL BIOLOGY COMMISSION CLINICAL BIOLOGY SECTION External Quality Assessment for Molecular
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationEvaluation of VACUETTE SECONDARY Tubes
Evaluation of VACUETTE SECODARY Tubes Background VACUETTE SECODARY Tubes are used as a secondary container for aliquoting, storing and transporting blood, blood components and urine from the primary tube
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationBEIPH Final Report. EQA Programme 2011 Chlamydia trachomatis (CTDNA11A) William G Mackay on behalf of QCMD and its Scientific Council April 2011
BEIPH Final Report EQA Programme 2011 Chlamydia trachomatis (CTDNA11A) William G Mackay on behalf of QCMD and its Scientific Council April 2011 Not to be reproduced or quoted without permission of QCMD.
More informationManitoba Cervical Cancer Screening Program. Operations & Statistical Report and 2006
anitoba Cervical Cancer Screening Program Operations & Statistical Report 2005 and 2006 1 MCCSP 2005-2006 Report ANITOBA CERVICAL CANCER SCREENING PROGRAM 2005 and 2006 Operations & Statistical Report
More information[TRANSLATION] Ministry of Health. Higher Health Council Session XLVI Combined Sections II and III. Meeting of 11th January 2007
[TRANSLATION] Ministry of Health Higher Health Council Session XLVI Combined Sections II and III Meeting of 11th January 2007 The Higher Health Council Combined Sections II and III HAVING REGARD TO the
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationEuropean Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs
European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs Introduction to the Survey The purpose of this project is to collect information regarding
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTitle: Seroprevalence of Human Papillomavirus Types 6, 11, 16 and 18 in Chinese Women
Author's response to reviews Title: Seroprevalence of Human Papillomavirus Types 6, 11, 16 and 18 in Chinese Women Authors: Jia Ji (jackie.j.ji@gmail.com) He Wang (hewangpeking@gmail.com) Jennifer S. Smith
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationCytology Update M Laing QEUH
Cytology Update M Laing QEUH Age change to 25 to 65 Age 25 to 50 Three yearly smear invitation Age 50 to 65 Five yearly smear invitation Women on non routine screening will be invited up to age 70 OUTCOME
More informationTISSUE TUMOR MARKER EXPRESSION IN
TISSUE TUMOR MARKER EXPRESSION IN NORMAL CERVICAL TISSUE AND IN CERVICAL INTRAEPITHELIAL NEOPLASIA, FOR WOMEN WHO ARE AT HIGH RISK OF HPV (HUMAN PAPILLOMA VIRUS INFECTION). Raghad Samir MD PhD Verksamhet
More informationNATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor 2017
a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a NATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor
More informationColposcopy. Attila L Major, MD, PhD
Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000
More informationPD-L1 Analyte Control DR
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
More informationto be notified: all parties involved in the graduated plan procedure. Annexes
Paul-Ehrlich-Institut Postfach 63207 Langen, Germany To all marketing authorisation holders of cellular blood preparations and therapeutic single plasmas as well as authorisation holders of stem cells
More informationAdvanced Molecular Diagnostic Systems
Advanced Molecular Diagnostic Systems Company Annual General Meeting November 26th 2008 Allen Bollands, Chief Executive Officer Genera Biosystems: Technology for Molecular Diagnostics GBI s core business:
More informationInnovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays
About the author Disclaimer EXECUTIVE SUMMARY Molecular diagnostic technologies Healthcare-associated infections Sexually transmitted HPVs HIV and hepatitis viruses Market outlook and forecasts Molecular
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationUnderstanding Your Pap Test Results
Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationCERVICAL CANCER FACTSHEET. What is cervical cancer?
CERVICAL CANCER FACTSHEET What is cervical cancer? ENGAGe is releasing a series of factsheets to raise awareness of gynaecological cancers and to support its network to work at a grassroots level. Take-up
More informationchapter 4. The effect of oncogenic HPV on transformation zone epithelium
chapter 4. The effect of oncogenic HPV on transformation zone epithelium CHAPTER 1 All squamous cervical cancer (and probably all cervical adenocarcinoma) is associated with oncogenic HPV, and the absence
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationFREQUENCY AND RISK FACTORS OF CERVICAL Human papilloma virus INFECTION
Arch. Biol. Sci., Belgrade, 66 (4), 1653-1658, 2014 DOI:10.2298/ABS1404653M FREQUENCY AND RISK FACTORS OF CERVICAL Human papilloma virus INFECTION IN WOMEN IN MONTENEGRO GORDANA MIJOVIĆ 1, TATJANA JOVANOVIĆ
More informationExternal Quality Assurance: Subregional experiences on RVF
Regional Seminar for OIE National Focal Points for Veterinary Laboratories Towards a culture of safety and quality External Quality Assurance: Subregional experiences on RVF Gian Mario Cosseddu, Istituto
More informationProfile Of Cervical Smears Cytology In Western Region Of Saudi Arabia
ISPUB.COM The Internet Journal of Gynecology and Obstetrics Volume 1 Number 2 Profile Of Cervical Smears Cytology In Western Region Of Saudi Arabia I Mansoor Citation I Mansoor. Profile Of Cervical Smears
More informationComparative evaluation of RNA and DNA approach for HPV diagnosis
Comparative evaluation of RNA and DNA approach for HPV diagnosis Dr. Cristina Lapucci Director of Geneticlab Laboratory and Specialist in Medical Genetics XII International Workshop Of Lower Genital Tract
More informationNorthern Ireland Cervical Screening Programme
Northern Ireland Cervical Screening Programme ANNUAL REPORT & STATISTICAL BULLETIN 2010-2011 1 Report produced by : Quality Assurance Reference Centre, PHA Date of Publication: September 2012 2 Contents
More informationQuality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024
Quality in Control ROS1 Analyte Control Product Codes: HCL022, HCL023 and HCL024 Contents What is ROS1? 2 The Role of ROS1 in Cancer 3 ROS1 Assessment 3 ROS1 Analyte Control Product Details 4 ROS1 Analyte
More informationManagement Algorithms for Abnormal Cervical Cytology and Colposcopy
Management Algorithms for Abnormal Cervical Cytology and Colposcopy Table of Contents Standard Colposcopic Definitions... 1 Guidelines for the Assessment of Abnormal Cervical Cytology... 2 Ia: Persistent
More informationPap plus HPV every 3 years with screening stopped at 65, 75 and 100 years; Pap plus HPV every 2 years with screening stopped at 65, 75 and 100 years.
Benefits and costs of using HPV testing to screen for cervical cancer Mandelblatt J S, Lawrence W F, Womack S M, Jacobsen D, Yo B, Hwang Y, Gold K, Barter J, Shah K Record Status This is a critical abstract
More informationBIRC Bern Interventional Radiology Course Bern, November Key not lecture: Innsbru
BIRC 2018 Bern Interventional Radiology Course Bern, 8. 10. November 2018 e Key not lecture: Bale, Prof. R. ck Innsbru Welcome Dear Colleagues minimally invasive, imagecontrolled procedures are becoming
More information2 Summary Under the auspices of the European Society for Clinical Nutrition and Metabolism (ESPEN) clinical practice guidelines on enteral nutrition w
1 publiziert bei: AWMF-Register Nr. 073/003 Klasse: S3 Introduction part of the ESPEN Guidelines on Enteral Nutrition Methodology for the development of the ESPEN Guidelines on Enteral Nutrition T. Schütz
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationERNDIM QA Scheme for qualitative urinary organic acid analysis. Annual Report 2010
UniversitätsKlinikum Heidelberg Universitätsklinik für Kinder- und Jugendmedizin Stoffwechselzentrum Heidelberg Stoffwechsellabor Im Neuenheimer Feld 430 69120 Heidelberg To Stoffwechselzentrum Heidelberg
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationPrevalence of HPV-16 genomic variant carrying a 63-bp duplicated sequence within the E1 gene in Slovenian women
Prevalence of HPV-16 genomic variant carrying a 63-bp duplicated sequence within the E1 gene in Slovenian women K E Y WORDS HPV-16, cervical cancer, E6-T350G variant A BSTRACT High-risk HPV, particularly
More informationQIAsure Methylation Test a breakthrough solution in Women s Health
QIAsure Página 1 de 12 Home Womens Health QIAsure Methylation Test a breakthrough solution in Women s Health Cervical cancer is the second most common cancer among women aged 15 to 44, affecting more than
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationBC Cancer Cervix Screening 2015 Program Results. February 2018
BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...
More informationKing s Research Portal
King s Research Portal DOI: 10.1111/cyt.12259 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA):
More informationUnderstanding My Pap Test Results
Form: D-8766 Understanding My Pap Test Results For patients of the Gynecology Oncology Clinic Read this pamphlet to learn more about: why you are having a Pap test how to understand your test results what
More informationCervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients
Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients Richard Hopley, MD, Alexandra Gillespie, MD* Laboratory Medicine 47:1:52-56 CLINICAL HISTORY Patients:
More informationWorkshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation
Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation May Yu Director of Cytology Laboratory Service Department of Anatomical & Cellular Pathology Prince of Wales Hospital Cervical
More informationScreening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More information